CN102875448B - 一种制备吲哚螺环戊烷衍生物的合成方法 - Google Patents

一种制备吲哚螺环戊烷衍生物的合成方法 Download PDF

Info

Publication number
CN102875448B
CN102875448B CN201210433883.6A CN201210433883A CN102875448B CN 102875448 B CN102875448 B CN 102875448B CN 201210433883 A CN201210433883 A CN 201210433883A CN 102875448 B CN102875448 B CN 102875448B
Authority
CN
China
Prior art keywords
reaction
derivative
derivant
indoles
cyclopentane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201210433883.6A
Other languages
English (en)
Other versions
CN102875448A (zh
Inventor
周庆发
储雪平
葛飞飞
陆涛
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
China Pharmaceutical University
Original Assignee
China Pharmaceutical University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by China Pharmaceutical University filed Critical China Pharmaceutical University
Priority to CN201210433883.6A priority Critical patent/CN102875448B/zh
Publication of CN102875448A publication Critical patent/CN102875448A/zh
Application granted granted Critical
Publication of CN102875448B publication Critical patent/CN102875448B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

本发明属于有机化学技术领域,具体为一种吲哚螺环戊烷衍生物合成方法。本发明使用3-丁炔-2-酮衍生物和3位具有炔亚甲基取代的吲哚酮衍生物为原料,在三苯基磷催化下通过[3+2]环加成反应合成一种丰富官能团的吲哚螺环戊烷衍生物,此类化合物骨架具有广谱的生物活性,在药物研发中具有潜在的应用前景。

Description

一种制备吲哚螺环戊烷衍生物的合成方法
技术领域
本发明涉及有机化学技术领域,具体为一种吲哚螺环戊烷衍生物的合成方法。
背景技术
吲哚螺环化合物是一类重要杂环化合物,广泛存在于天然产物和药物活性成分当中,具有多种药理活性。例如,其对NNRTIs型HIV-1具有抑制活性(Jiang T.Bioorg.Med.Chem.Lett.2006,16,2105)、对甘氨酸受体具有拮抗作用(Hershenson,F.M.;Prodan,K.A.,et al.J.Med.Chem.1977,20,1448)、以及对肿瘤具有抑制活性(Numata,A.,Takada,T,et al.J.Tetrahedron lett.1993,34,2355)。因此,吲哚螺环化合物的合成受到人们的广泛关注。随着吲哚合成化学的发展,氮杂、氧杂等杂环吲哚螺环衍生物的一步合成方法相继被发现,但吲哚螺环戊烷衍生物的简便合成方法鲜见报道。因此,开发以简单结构的起始原料,一步合成吲哚螺环戊烷衍生物的方法具有重要的实际应用价值。本发明提供了一种简单、方便、新颖的制备丰富官能团的吲哚螺环戊烷衍生物的新技术。
发明内容
本发明使用吲哚酮衍生物1与3-丁炔-2-酮衍生物2在三苯基磷催化下发生[3+2]环化反应,制得吲哚螺环戊烷类衍生物3,其反应式如下:
Figure BSA00000799237200011
其中化合物1为吲哚酮衍生物,R1为H或CH3、OCH3等各种供电子基团或F、Cl、CF3等各种吸电子基团,R2为Ph或4-Me-C6H4、4-MeOC6H4、3,4-MeOC6H3、4-Cl-C6H4、3-Cl-C6H4、2-Cl-C6H4、4-F-C6H4等含各种取代基的苯基及2-naphthyl,2-furanyl等基团,化合物2为3-丁炔-2-酮衍生物,R3为Ph或4-Me-C6H4,4-MeOC6H4,3,4-MeOC6H3等各种含供电子基团的芳基或4-F-C6H4,4-CF3-C6H4,4-Cl-C6H4等各种含吸电子基团的芳基。
具体操作步骤为:
吲哚酮类衍生物1,3-丁炔-2-酮衍生物2溶于有机溶剂中,加入有机磷试剂,于室温反应至反应基本完全,浓缩后用柱层析分离得到相应的吲哚螺环戊烷类化合物。
该反应起始原料易得,条件温和,合成路线简短、操作方便,成本较低,而且通过此法合成的吲哚螺环戊烷衍生物具有潜在的生物活性,在新药研发领域有较好的应用前景。
本发明的较佳反应条件为:
(1)催化剂为PPh3
(2)吲哚酮类衍生物、PPh3与3-丁炔-2-酮衍生物的摩尔比例为1∶0.5∶2;
(2)溶剂为二氯甲烷∶乙酸乙酯=9∶1;
(3)反应温度为室温。
具体实施方式
下面的实施例是对本发明的进一步说明,而不是限制本发明的范围。
实施例1化合物3a的合成
Figure BSA00000799237200021
(E)-1-苄基-3-(3-苯基-2-丙炔基)二氢吲哚-2-酮(0.1mmol),4-苯基-3-丁炔-2-酮(0.2mmol)溶于1mL二氯甲烷/乙酸乙酯(9/1)中,加入催化剂PPh3(0.05mmol),室温反应48h,浓缩后用柱层析分离得到相应的吲哚螺环戊烷衍生物3a,收率63%。IR(KBr):v=3059,3028,1718,1690,1619,1588,1447,1362,1184,1168,908,870,762,696cm-1.1H NMR(500MHz,CDCl3)δ7.82(s,1H),7.35-7.27(m,3H),7.24-7.21(m,3H),7.16-7.05(m,7H),6.97(t,J=8.0Hz,2H),6.89-6.86(m,2H),6.82(d,J=7.5Hz,2H),6.78(d,J=8.0Hz,1H),5.08(d,J=16.0Hz,1H),4.36(d,J=16.0Hz,1H),3.85(dd,J=11.5,7.5Hz,1H),3.16(dd,J=13.0,8.0Hz,1H),2.98(dd,J=13.0,6.5Hz,1H).13C NMR(125MHz,CDCl3)δ202.44,175.67,142.82,138.63,136.17,135.24,134.25,131.74,130.99,129.74,129.37,129.04,128.80,128.30,128.20,128.13,127.54,127.24,124.35,123.03,122.53,109.67,86.13,85.69,59.46,44.38,42.52,38.65.HRMS(ESI):calcd.for C34H26NO2[M+H]+480.1958;found480.1951.
实施例2化合物3b的合成
(E)-1-苄基-5-氯-3-(3-苯基-2-丙炔基)二氢吲哚-2-酮(0.1mmol),4-苯基-3-丁炔-2-酮(0.2mmol)溶于1mL二氯甲烷/乙酸乙酯(9/1)中,加入催化剂PPh3(0.05mmol),室温反应48h,浓缩后柱层析分离得到相应的吲哚螺环戊烷衍生物3b,收率72%。1H NMR(300MHz,CDCl3)δ7.84(s,1H),7.24(d,J=2.1Hz,2H),7.23-7.19(m,2H),7,19-7.17(m,2H),7.17-7.01(m,6H),7.00-6.94(m,2H),6.80(d,J=7.2Hz,2H),6.68(d,J=8.3Hz,1H),5.04(d,J=15.8Hz,1H),4.37(d,J=15.8Hz,1H),3.83(dd,J=10.8,8.0Hz,1H),3.21(dd,J=18.0,8.0Hz,1H),2.96(dd,J=18.0,10.8Hz,1H).13C NMR(75MHz,CDCl3)δ201.97,174.42,166.50,154.59,148.63,141.49,141.37,139.20,135.41,135.22,134.79,134.05,133.99,133.08,132.16,131.74,130.04,129.89,129.25,129.16,129.02,128.93,128.90,128.70,128.60,128.52,128.40,128.31,128.17,127.97,127.79,127.55,127.28,125.01,123.37,122.23,120.79,110.57,110.48,105.16,97.35,85.75,59.33,44.49,42.36,38.52.HRMS(ESI):calcd.for C34H25ClNO2[M+H]+514.1568;found514.1567.
实施例3化合物3c的合成
Figure BSA00000799237200032
(E)-1-苄基-5-氯-3-(3-苯基-2-丙炔基)二氢吲哚-2-酮(0.1mmol),4-苯基-3-丁炔-2-酮(0.2mmol)溶于1mL二氯甲烷/乙酸乙酯(9/1)中,加入催化剂PPh3(0.05mmol),室温反应48h,浓缩后柱层析分离得到相应的吲哚螺环戊烷衍生物3c,收率58%。IR(KBr):v=3057,3030,2920,2852,1731,1718,1617,1558,1541,1508,1490,1455,1450,1186,1175,861,758,694cm-1.1H NMR(300MHz,CDCl3)δ7.84(s,1H),7.28-7.17(m,6H),7.14-7.02(m,5H),6.99-6.92(m,4H),6.81(d,J=7.2Hz,2H),6.68(dd,J=9.3,4.2Hz,1H),5.06(d,J=15.9Hz,1H),4.37(d,J=15.9Hz,1H),3.85(dd,J=11.1,8.1Hz,1H),3.21(dd,J=18.0,8.1Hz,1H),2.95(dd,J=18.0,11.1Hz,1H).13C NMR(75MHz,CDCl3)δ201.98,175.56,160.92,139.18,138.88,135.52,134.98,134.03,131.72,129.86,129.37,129.23,128.92,128.69,128.49,128.30,128.16,127.75,127.32,122.32,115.43,114.77,112.92,110.15,86.00,85.82,44.57,42.41,38.51,29.84.HRMS(ESI):calcd.for C34H25FNO2[M+H]+498.1864;found498.1862.
实施例4化合物3d的合成
(E)-1-苄基-3-{3-(4-氟代苯基)-2-丙炔基}二氢吲哚-2-酮(0.1mmol),4-苯基-3-丁炔-2-酮(0.2mmol)溶于1mL二氯甲烷/乙酸乙酯(9/1)中,加入催化剂PPh3(0.05mmol),室温反应48h,浓缩后柱层析分离得到相应的吲哚螺环戊烷衍生物3e,收率50%。IR(KBr):v=3066,3032,2922,2854,1718,1698,1654,1616,1609,1558,1506,1488,1458,1362,1179,1155,831,754,699cm-1.1H NMR(300MHz,CDCl3)δ7.81(s,1H),7.42-7.27(m,5H),7.22-7.15(m,2H),7.12-7.06(m,3H),7.03-6.96(m,2H),6.86-6.77(m,6H),5.08(d,J=15.9Hz,1H),4.33(d,J=15.6Hz,1H),3.83(dd,J=15.0,6.8Hz,1H),3.15(dd,J=18.0,8.0Hz,1H),2.97(dd,J=18.3,11.7Hz,1H).13C NMR(75MHz,CDCl3)δ202.30,175.60,164.18,141.18,138.70,136.09,135.28,134.23,133.65,133.63,131.44,129.78,129.36,129.04,128.79,128.14,127.61,127.30,124.30,123.03,115.61,109.62,85.85,84.61,44.38,42.44,38.61,35.88.HRMS(ESI):calcd.for C34H25F NO2[M+H]+498.1864;found498.1871.
实施例5化合物3e的合成
Figure BSA00000799237200051
(E)-1-苄基-3-{3-(2-氯代苯基)-2-丙炔基}二氢吲哚-2-酮(0.1mmol),4-苯基-3-丁炔-2-酮(0.2mmol)溶于1mL二氯甲烷/乙酸乙酯(9/1)中,加入催化剂PPh3(0.05mmol),室温反应48h,浓缩后柱层析分离得到相应的吲哚螺环戊烷衍生物3f,收率61%。IR(KBr):v=3064,3031,2919,2849,1716,1698,1654,1616,1558,1515,1179,753,696cm-1.1H NMR(300MHz,CDCl3)δ7.81(s,1H),7.31-7.14(m,7H),7.10-6.97(m,7H),6.84(dd,J=8.0,1.5Hz,1H),6.78-6.76(m,3H),5.06(d,J=16.0Hz,1H),4.36(d,J=16.0Hz,1H),3.91(dd,J=12.0,8.0Hz,1H),3.20(dd,J=18.0,8.0Hz,1H),3.04(dd,J=18.0,11.5Hz,1H).13C NMR(300MHz,CDCl3)δ202.23,175.57,142.80,138.62,136.24,135.90,135.24,134.18,133.71,131.38,130.79,129.73,129.34,129.12,128.94,128.71,128.12,127.56,127.34,126.29,124.45,123.15,122.49,109.84,91.38,82.39,59.28,44.36,42.49,38.67.HRMS(ESI):calcd.for C34H25ClNO2[M+H]+514.1568;found514.1578.
实施例6化合物3f的合成
Figure BSA00000799237200052
(E)-1-苄基-3-(3-苯基-2-丙炔基)二氢吲哚-2-酮(0.1mmol),4-(4-氟-苯基)-3-丁炔-2-酮(0.2mmol)溶于1mL二氯甲烷/乙酸乙酯(9/1)中,加入催化剂PPh3(0.05mmol),室温反应48h,浓缩后柱层析分离得到相应的吲哚螺环戊烷衍生物3h,收率43%。IR(KBr):v=3061,3031,2934,2903,1725,1701,1696,1628,1612,1599,1506,1468,1225,1180,1113,1094,894,843,769,752,695cm-1.1H NMR(300MHz,CDCl3)δ7.75(s,1H),7.63-7.50(m,1H),7.47-7.26(m,4H),7.25-6.98(m,8H),6.90-6.71(m,5H),5.07(d,J=15.6Hz,1H),4.47(d,J=15.6Hz,1H),3.87-3.80(dd,J=12.3,7.8Hz,1H),3.17(dd,J=18.0,8.1Hz,1H),2.98(dd,J=18.0,11.4Hz,1H).13C NMR(75MHz,CDCl3)δ202.27,175.60,165.02,142.70,142.32,137.33,136.99,135.59,135.47,131.69,131.55,131.10,129.15,128.82,128.32,128.19,127.68,127.40,124.44,123.09,115.47,109.66,109.13,86.00,85.75,44.40,43.35,42.46,38.71.HRMS(ESI):calcd.for C34H25F NO2[M+H]+498.1864;found498.1872。

Claims (4)

1.一种吲哚螺环戊烷衍生物的合成方法,包含以下步骤:其特征在于3位具有炔亚甲基取代的吲哚酮衍生物在温和条件下与3-丁炔-2-酮衍生物反应,在三苯基膦催化下发生环合反应,制得一种吲哚螺环戊烷类化合物,其反应式如下:
Figure FSB0000123709450000011
具体操作步骤为:
吲哚酮类衍生物1,3-丁炔-2-酮衍生物2溶于有机溶剂中,加入三苯基膦,于室温反应至反应基本完全,浓缩后柱层析分离得到相应的吲哚螺环戊烷类化合物,
R1为H或F,Cl;
R2为Ph或2-Cl-C6H4,4-F-C6H4
R3为Ph或4-F-C6H4
2.如权利要求1所述的方法,其特征在于吲哚酮类衍生物、有机磷试剂与3-丁炔-2-酮衍生物的摩尔比例为1∶0.5∶2。
3.如权利要求1所述的方法,溶剂为二氯甲烷∶乙酸乙酯=9∶1。
4.如权利要求1所述的方法,反应温度为室温。
CN201210433883.6A 2012-11-05 2012-11-05 一种制备吲哚螺环戊烷衍生物的合成方法 Expired - Fee Related CN102875448B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201210433883.6A CN102875448B (zh) 2012-11-05 2012-11-05 一种制备吲哚螺环戊烷衍生物的合成方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201210433883.6A CN102875448B (zh) 2012-11-05 2012-11-05 一种制备吲哚螺环戊烷衍生物的合成方法

Publications (2)

Publication Number Publication Date
CN102875448A CN102875448A (zh) 2013-01-16
CN102875448B true CN102875448B (zh) 2014-07-02

Family

ID=47477003

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201210433883.6A Expired - Fee Related CN102875448B (zh) 2012-11-05 2012-11-05 一种制备吲哚螺环戊烷衍生物的合成方法

Country Status (1)

Country Link
CN (1) CN102875448B (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104086477B (zh) * 2014-07-15 2017-04-12 西华师范大学 光学活性螺环戊烷‑1,3′‑吲哚及其衍生物的制备方法
CN107778320A (zh) * 2017-10-23 2018-03-09 青岛大学 一种螺环异恶唑啉类化合物的合成方法
CN111704571A (zh) * 2020-07-20 2020-09-25 南宁师范大学 光学活性2-芳基螺环[环戊烷-1,3’-吲哚]-3-甲醛的制备方法
CN114805182A (zh) * 2022-04-29 2022-07-29 常州大学 一种可见光催化合成吲哚螺环丙烷类化合物的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8627859D0 (en) * 1986-11-21 1986-12-31 Pilkington Brothers Plc Spiro-oxazine compounds
EP0823904A4 (en) * 1995-04-19 1998-09-09 Merck & Co Inc METHOD FOR PRODUCING SPIROINDOLINES
CN100345851C (zh) * 2004-01-02 2007-10-31 上海药明康德新药开发有限公司 螺二氢吲哚类模板化合物及其制备方法
CN102627650B (zh) * 2012-03-08 2015-07-08 徐州师范大学 手性四氢吡咯-3,2′-氧化吲哚螺环化合物及其合成方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
孙亮.《STN》.《STN》.2014, *

Also Published As

Publication number Publication date
CN102875448A (zh) 2013-01-16

Similar Documents

Publication Publication Date Title
Paul et al. Dual role of the polymer supported catalyst PEG-OSO3H in aqueous reaction medium: synthesis of highly substituted structurally diversified coumarin and uracil fused spirooxindoles
Rajesh et al. Facile ionic liquid-mediated, three-component sequential reactions for the green, regio-and diastereoselective synthesis of furocoumarins
Han et al. Efficient synthesis of pentasubstituted pyrroles via one-pot reactions of arylamines, acetylenedicarboxylates, and 3-phenacylideneoxindoles
Zhou et al. Synthesis of Six-Membered Spirocyclic Oxindoles with Five Consecutive Stereocenters in an Asymmetric Organocatalytic One-Pot Michael/Michael/Aldol Addition Sequence
Yin et al. Pyrrole strategy for the γ-lactam-containing Stemona alkaloids:(±) stemoamide,(±) tuberostemoamide, and (±) sessilifoliamide A
CN102875448B (zh) 一种制备吲哚螺环戊烷衍生物的合成方法
Pei et al. Synthesis of optically active dihydropyrans from asymmetric [4+ 2] cycloaddition of β, γ-unsaturated α-ketoesters with allenic esters
Dassonneville et al. [2+ 2+ 2] Cycloadditions of alkynylynamides–A total synthesis of perlolyrine and the first total synthesis of “isoperlolyrine”
Hao et al. NHC-catalyzed ester activation: access to sterically congested spirocyclic oxindoles via reaction of α-aryl esters and unsaturated imines
Pradhan et al. Synthesis of 3, 4-dihydropyridin-2-one derivatives in convergent mode applying bio catalyst vitamin B1 and polymer supported catalyst PEG–SO3H from two different sets of building blocks
CN102850274B (zh) 一种合成手性螺环吡唑啉酮的方法
Srivastava et al. (±)-CSA catalyzed Friedel–Crafts alkylation of indoles with 3-ethoxycarbonyl-3-hydoxyisoindolin-1-one: an easy access of 3-ethoxycarbonyl-3-indolylisoindolin-1-ones bearing a quaternary α-amino acid moiety
CN111423394B (zh) 1,3,4-恶二唑杂环化合物的合成方法
Yang et al. Diastereoselective synthesis of Rauhut–Currier-type adducts via an unexpected α-addition of α, β-unsaturated γ-butyrolactams to coumarin derivatives
Mohammadizadeh et al. A novel, convenient, and efficient procedure for the synthesis of spiroisoindoline-1, 5′-oxazolidine derivatives
Tang et al. Highly diastereoselective synthesis of cyclopropane-fused spiro-pseudoindoxyl derivatives through [2+ 1] annulation of 2-ylideneoxindoles and sulfonium bromides
Feng et al. Tunable Synthesis of Functionalized Cyclohexa-1, 3-dienes and 2-Aminobenzophenones/Benzoate from the Cascade Reactions of Allenic Ketones/Allenoate with Amines and Enones
Park et al. Organocatalytic and late-stage CH-functionalization enabled asymmetric synthesis of communesin F and putative communesins
Liu et al. N-heterocyclic carbene-catalyzed [3+ 2] annulation of 3, 3′-bisoxindoles with α-bromoenals: enantioselective construction of contiguous quaternary stereocenters
CN104031050A (zh) 手性螺环磷酸催化合成光学活性苯氮卓并吲哚衍生物的方法
Huang et al. Cp∗ Rh/Ag catalyzed C–H activation/cyclization sequences of NH-sulfoximines to fused aza-polyheterocycles under gentle conditions
Hemamalini et al. An easy access to novel sugar-based spirooxindole-pyrrolidines or-pyrrolizidines through [3+ 2] cycloaddition of azomethine ylides
Lu et al. Montmorillonite K-10-catalyzed intramolecular rearrangement of vinylidenecyclopropanes
Wang et al. Selective synthesis of 3-methylene-2, 3-dihydrofurans or 1, 2, 4-trisubstituted furans via tandem reactions of allenic ketones with α-chloro β-keto esters or ketones
CN102070503B (zh) 一种制备吡咯衍生物的方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20140702

Termination date: 20171105